Frontlight ResearchEarly access
Active, not recruitingPhase 3
Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX).
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- France35 sites in 1 countryChoose a country to see its sites
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 272 people, planned
- Started
- 7 Apr 2022
- Ended
- 7 Oct 2026
- Type of study
- Interventional
- Record updated
- 27 May 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Age ≥ 18 years ≤ 80 years
- Diagnosis of ITP whatever the duration of the disease (newly diagnosed or relapsed) according to the standard definition
- Platelet count ≤ 20 x 109/L
- Any cutaneous and/or any mucosal bleeding manifestations
- Affiliated to a social security regime
- Written consent from patient
Who cannot take part
- Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants
- Previous non-response to IVIg or DEX
- Treatment with prednisone (1 mg/kg per day) for more than 3 days
- Symptomatic COVID-19 disease
- Ongoing viral infection (uncontrolled HIV, Viral hepatitis, herpes, varicella, zona)
- Uncontrolled diabetes (Acido-cetosis)
- Ongoing severe infection
- Severe Renal insufficiency (DFG < 45 ml.min.1.73m2)
- Severe Cardiac insufficiency (FEVG < 30 %)
- Life-threatening bleeding defined as Intracranial hemorrhage and/or active organ bleeding (GI tract, urinary tract or menorrhagia with at least a 2 g/dl decrease of hemoglobin value from baseline)
- Psychotic state not yet controlled by treatment
- Inability or refusal to understand or refusal to sign the informed consent from study participation
- Persons deprived of their liberty by judicial or administrative decision
- Persons under legal protection (guardianship, curatorship)
- Pregnant or breastfeeding woman or ineffective contraception
- Ongoing anticoagulation treatment (Therapeutic Low molecular weight heparins (LMWHs), direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs))
- Any contraindications to the prescribed Ig IV or prednisone patent medicine and to Neofordex®
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To demonstrate the non-inferiority in term of short-term response of oral dexamethasone given at 40 mg on days 1 to 4 compared to IVIg given at 1g/kg on days 1 and 2 in combination with prednisone (1 mg/kg per day for 3 weeks) in adult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestations.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX)
- Record updated
- 27 May 2025